Importantly, the SDMA mark was significantly reduced in the xenograft tissues of mice treated with LLY-283 as compared to the vehicle-treated mice (Fig. 6d), suggesting that the reduction of tumor size and concomitant increase in survival are due to the disruption of the enzymatic function of PRMT5. Here, PRMT5 is linked to neoplasm.